I-mab Biopharma (Hangzhou) Co., Ltd. announced that it will receive equity funding for $19 million from returning investor I-Mab on February 7, 2024. The transaction is expected to be close by the end of March 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.75 USD | -1.13% | -3.31% | -7.89% |
Apr. 18 | Verastem Names John Hayslip as Chief Medical Officer | MT |
Apr. 15 | I-Mab Announces Chief Medical Officer Changes | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.89% | 143M | |
+32.09% | 694B | |
+29.39% | 593B | |
-1.34% | 371B | |
+20.34% | 331B | |
+7.39% | 290B | |
+14.25% | 239B | |
-3.03% | 209B | |
+10.02% | 209B | |
+8.49% | 169B |
- Stock Market
- Equities
- IMAB Stock
- News I-Mab
- I-mab Biopharma Co., Ltd. announced that it expects to receive CNY 19 million in funding from I-Mab